Elad Berkman is co-founder and CTO of PhaseV, which specializes in causal machine learning (ML) for clinical development. A trained physicist turned data scientist, Berkman has led dozens of operations research studies. He previously served as VP data science at transit technology company Via, leading the company's machine learning and data science efforts. Berkman has authored numerous patents at the intersection of ML and transportation.
When a single pivotal trial can determine the fate of an entire program, success depends less on marginal gains in speed or cost and more on building robust, adaptive trial designs that actively manage uncertainty and protect the probability of a positive outcome.
